Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States

Coherus BioSciences, Inc. announced that the FDA has granted Orphan Drug Designation for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer.